Oct 05th 2012 - Edison Investment Research today published a report on Exonhit entitled "Prodromal Attack". In summary, the report says:
The recent failure of two high-profile, late stage clinical candidates for Alzheimer’s disease (AD) has highlighted the need to target future therapeutic interventions earlier in the course of this disease. This strengthens the case for using diagnostic tools such as Exonhit’s AclarusDx, both in trials, and if the products are ultimately successful, in clinical practice. Exonhit’s investment case is largely based on the commercial potential of AclarusDx, its blood-based aid for the diagnosis of AD, although it also has an interest in the Phase II trial stage neuropathic pain programme, EHT/AGN 0001, which is partnered with Allergan and Bristol-Myers Squibb.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »